List of Excipients in Branded Drug ASENAPINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	ASENAPINE	asenapine maleate	59762-1091	GELATIN
Greenstone LLC	ASENAPINE	asenapine maleate	59762-1091	MANNITOL
Greenstone LLC	ASENAPINE	asenapine maleate	59762-1091	SUCRALOSE

Generic Drugs Containing ASENAPINE

Company	Ingredient	NDC	Excipient
Sigmapharm Laboratories LLC	asenapine	42794-016	ANHYDROUS CITRIC ACID
Sigmapharm Laboratories LLC	asenapine	42794-016	BUTYLATED HYDROXYTOLUENE
Sigmapharm Laboratories LLC	asenapine	42794-016	COPOVIDONE
Sigmapharm Laboratories LLC	asenapine	42794-016	CROSPOVIDONE
Sigmapharm Laboratories LLC	asenapine	42794-016	MAGNESIUM STEARATE
Sigmapharm Laboratories LLC	asenapine	42794-016	MALTODEXTRIN
Sigmapharm Laboratories LLC	asenapine	42794-016	MANNITOL

What are the Most Frequently-Used Excipients in ASENAPINE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
3	ASPARTAME
4	BUTYLATED HYDROXYANISOLE
5	BUTYLATED HYDROXYTOLUENE
3	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE
4	CROSPOVIDONE

Asenapine Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Asenapine has two differentiated dosage forms: sublingual tablets marketed as Saphris and a transdermal system marketed as Secuado. The strongest excipient opportunities are in taste masking, rapid oral disintegration, moisture control, patch adhesion, skin tolerability, and lifecycle reformulation. Generic competition is established for sublingual asenapine, while the transdermal system remains more difficult to replicate because of formulation, device, adhesive, and clinical-performance requirements.

What dosage forms and excipients are used for asenapine?

Asenapine maleate is approved for schizophrenia and bipolar I disorder in adults. The product strategy differs sharply by dosage form.

Product	Dosage form	Route	Strengths	Primary formulation challenge
Saphris	Sublingual tablet	Sublingual	5 mg, 10 mg	Rapid dissolution, taste, moisture sensitivity
Generic asenapine	Sublingual tablet	Sublingual	5 mg, 10 mg	Bioequivalence, sensory equivalence, packaging
Secuado	Transdermal system	Transdermal	3.8, 5.7, 7.6 mg/24 hours	Flux control, adhesion, irritation, dose delivery

The Saphris label identifies gelatin and mannitol among the inactive ingredients. The tablet is designed to dissolve under the tongue, and patients are instructed not to swallow, split, chew, or drink immediately after administration.[1]

The Secuado system is a drug-in-adhesive transdermal patch. Its commercial performance depends on the combined behavior of asenapine, the adhesive matrix, backing layer, release liner, and skin-contact interface.[2]

Which excipients are relevant to sublingual asenapine?

The most commercially relevant excipient functions are:

• Mannitol as a water-soluble filler and mouthfeel modifier.
• Gelatin as a structural and rapidly dissolving matrix component.
• Disintegrants or superdisintegrants, where permitted by the target formulation, to accelerate wetting and breakup.
• Flavoring or sweetening systems to reduce bitterness.
• Moisture-control agents and protective packaging to preserve tablet integrity.
• Lubricants and glidants selected to avoid slowing dissolution.

Asenapine has a pronounced bitter taste. A conventional swallowed tablet approach would not replicate the intended route of administration. The excipient system must support rapid release in a low-volume saliva environment while limiting the time available for taste perception.

Which excipients are relevant to the transdermal patch?

A transdermal asenapine product generally requires:

• A pressure-sensitive adhesive that maintains contact over the labeled wear period.
• A drug-compatible polymer matrix.
• Tackifiers or plasticizers that balance adhesion and flexibility.
• A backing layer that limits drug loss and protects the system.
• A release liner that supports manufacturing, storage, and clean application.
• Skin-tolerability controls that reduce erythema, itching, and sensitization.

The key commercial issue is not the identity of a single excipient. It is the performance of the complete adhesive system. A change in polymer, plasticizer, or tackifier can alter drug flux, residual drug, crystallization, adhesion, and irritation.

What excipient strategy is strongest for asenapine sublingual tablets?

A robust sublingual strategy prioritizes fast wetting, low tablet mass, physical stability, and acceptable mouthfeel.

Rapid disintegration and dissolution

Sublingual products must dissolve under limited fluid conditions. Conventional oral disintegration data are insufficient. Development teams should evaluate:

• Disintegration in artificial saliva.
• Dissolution at low volumes.
• Tablet residence time under the tongue.
• Drug release after partial wetting.
• Sensory duration and bitterness intensity.
• Mechanical strength after exposure to humidity.

The formulation should avoid excessive hydrophobic lubricant or overcompression because both can delay wetting. A highly porous structure can improve dissolution but may increase friability and packaging damage.

Taste masking

Taste masking is a major opportunity for differentiated asenapine products. Potential approaches include:

• Polymer complexation.
• Ion-exchange resins.
• Lipid or wax microcoatings.
• Cyclodextrin complexes.
• Multiparticulate taste-masking systems.
• Flavor systems combined with saliva-triggered release.

The main constraint is that taste masking cannot materially delay sublingual drug release. A coating that works for a swallowed tablet may fail in a sublingual product because it reduces drug availability during the short administration window.

Ion-pairing and complexation strategies are particularly relevant because asenapine is administered as the maleate salt. Developers must confirm that a taste-masking complex does not reduce the free-drug fraction or produce unacceptable variability between patients with different saliva volumes and pH.

Moisture protection

Sublingual tablets can be sensitive to humidity, mechanical stress, and premature softening. High-value packaging options include:

• Unit-dose aluminum-aluminum blister packs.
• High-barrier multilayer films.
• Desiccant-integrated cartons.
• Low-moisture manufacturing environments.
• Moisture-resistant overwraps.

Packaging can be a commercial differentiator where the tablet formulation itself is difficult to change without raising bioequivalence risk. Improved unit-dose packaging may extend shelf life, reduce tablet breakage, and support adherence in institutional or outpatient settings.

What formulation patents protect asenapine products?

Asenapine patent protection has historically covered the active compound, pharmaceutical compositions, salts, dosage forms, and therapeutic use. The key branded-product protection has focused on the approved sublingual formulation and later transdermal delivery technology.

Compound and composition patents

The foundational asenapine patent estate originated with Organon and related entities. Compound-level protection for asenapine expired before the later commercial lifecycle of Saphris. The remaining commercial relevance shifted toward formulation, dosage-form, method-of-use, and transdermal-system rights.

For generic applicants, the practical distinction is between:

1. Freedom to market the active ingredient.
2. Freedom to market a sublingual formulation.
3. Freedom to market a transdermal system.
4. Freedom to use patented methods of treating schizophrenia or bipolar disorder.
5. Freedom to use protected manufacturing processes.

A patent search should treat these as separate claim categories. Expiration of compound claims does not eliminate formulation or method-of-use exposure.

Sublingual formulation protection

The sublingual tablet may be protected through claims directed to:

• Asenapine maleate compositions.
• Rapidly dissolving oral dosage forms.
• Specific excipient ratios.
• Manufacturing processes.
• Packaging and moisture-control systems.
• Treatment methods using defined doses or patient populations.

Not every formulation patent appears in the FDA Orange Book. The Orange Book primarily records patents submitted by the NDA holder that the FDA determines to claim the drug substance, drug product, or approved method of use.[3]

Transdermal formulation protection

Secuado has a broader technical barrier because a competing product may need to reproduce:

• Drug loading.
• Adhesive composition.
• Drug release rate.
• Patch dimensions.
• Wear time.
• Residual drug profile.
• Skin permeation performance.
• Application and removal characteristics.

A generic transdermal applicant faces both patent risk and development risk. Even when a patent claim can be designed around, the alternative adhesive system must still demonstrate comparable delivery and acceptable adhesion and dermatologic safety.

What is the Orange Book status of asenapine?

The Orange Book is the primary FDA source for listed patents, exclusivity, therapeutic-equivalence ratings, and approved dosage forms.[3]

Product category	Regulatory status	Commercial implication
Saphris sublingual tablets	NDA product with generic competition	Price pressure and substitution risk
Generic asenapine sublingual tablets	ANDA pathway	Established competitive route
Secuado transdermal system	NDA product	Higher formulation and device barriers
Biosimilar pathway	Not applicable	Asenapine is a small molecule, not a biologic

Asenapine does not present biosimilar risk because it is a chemically synthesized small-molecule drug. Competitive entry occurs through ANDAs, not abbreviated biosimilar applications.

When does asenapine lose exclusivity?

Asenapine’s compound exclusivity has expired. The commercial question is no longer basic molecule exclusivity. It is the scope and enforceability of residual formulation, method-of-use, and transdermal patents.

Saphris received FDA approval in 2009. Secuado received FDA approval in 2019.[1,2] The relevant exclusivity periods included standard new-chemical-entity and product-specific protections, but the current market is primarily governed by patent status and generic approvals.

A useful exclusivity timeline is:

Year	Event
2009	FDA approval of Saphris sublingual tablets
2010s	Compound and early product exclusivity periods expired or diminished
2019	FDA approval of Secuado transdermal system
2020s	Generic sublingual asenapine competition expanded
Current market	Sublingual product exposed to generic pricing; transdermal product retains higher technical barriers

Exact patent expiration dates should be determined patent-by-patent from the current Orange Book, USPTO records, and terminal-disclaimer data. Patent term adjustment, patent-term extension, pediatric exclusivity, and terminal disclaimers can affect the effective date.

Which companies are challenging asenapine, and what is the Paragraph IV risk?

Generic companies have pursued asenapine sublingual tablets through the ANDA process. The commercial risk is materially higher for Saphris than for Secuado because the sublingual dosage form is easier to manufacture and evaluate than a transdermal system.

A Paragraph IV certification can challenge an Orange Book-listed patent on grounds that the patent is invalid, unenforceable, or not infringed. The NDA holder may file an infringement action within 45 days, triggering a statutory stay of FDA approval for up to 30 months, subject to court action and statutory exceptions.[4]

Generic launch scenarios

Scenario	Likely market effect
First generic approval without litigation delay	Rapid price erosion and pharmacy substitution
Multiple generic approvals	Accelerated erosion, contracting pressure, lower net price
At-risk launch after litigation	Potential damages exposure and later market disruption
Settlement with delayed entry	Predictable erosion date but preserved branded revenue until entry
No successful challenge to transdermal patents	Secuado retains differentiated positioning

The most important risk for the sublingual product is not a single generic entrant. It is the transition from one generic competitor to several suppliers. Once therapeutic equivalence is established and payer substitution expands, excipient differentiation has limited ability to preserve price unless it produces a meaningful adherence, tolerability, or packaging advantage.

How strong is the asenapine patent estate?

The estate is stronger for the transdermal system than for the mature sublingual tablet.

Patent dimension	Sublingual asenapine	Transdermal asenapine
Compound claims	Weak or expired	Weak or expired
Basic composition claims	Limited remaining value	Less central
Excipient claims	Potentially narrow	Potentially important
Manufacturing claims	Moderate if process-specific	High if adhesive and coating-specific
Device-system claims	Limited	Significant
Bioequivalence barrier	Moderate	High
Design-around difficulty	Moderate	High
Generic substitution risk	High	Lower

Patent strength depends on claim breadth, written-description support, prosecution history, prior art, enablement, and the ability of a generic applicant to use a non-infringing excipient system. Narrow claims directed to a precise polymer blend or loading range may be valuable commercially but vulnerable if a competitor can change the adhesive architecture.

What commercial opportunities exist in asenapine excipients?

The most attractive opportunities are products that solve a recognized administration problem rather than simply replace an inactive ingredient.

1. Premium sublingual taste-masked product

A developer could pursue a new formulation with:

• Reduced bitterness.
• Faster dissolution.
• Lower tablet mass.
• Improved humidity stability.
• Better unit-dose packaging.
• Pediatric or geriatric administration advantages, where clinically and regulatorily appropriate.

The strongest commercial case would combine sensory improvement with adherence data. A taste-masked product without a clear clinical, adherence, or convenience benefit may face limited reimbursement support.

2. Generic line extension

Generic manufacturers can use excipient and packaging optimization to reduce manufacturing costs and improve supply reliability. Opportunities include:

• Direct-compression formulations.
• Lower-cost gelatin or non-gelatin matrices.
• Improved tableting robustness.
• Reduced dependence on specialty processing.
• High-barrier blister packaging.
• Alternate suppliers for mannitol and gelatin.

The principal regulatory risk is that changing excipients can affect dissolution, local exposure, and sensory characteristics. The formulation must remain within the relevant ANDA bioequivalence and product-quality framework.

3. Non-gelatin sublingual tablets

A non-gelatin formulation could address religious, dietary, vegetarian, or supply-chain concerns. Potential matrix systems include modified starches, pullulan, cellulose derivatives, and other film-forming polymers.

The development challenge is to match the mechanical strength and dissolution profile of the reference product without creating a gummy mouthfeel or prolonged residence time.

4. Transdermal adhesive technology

Specialty excipient suppliers may pursue licensing or co-development with:

• Acrylic pressure-sensitive adhesives.
• Silicone adhesives.
• Polyisobutylene systems.
• Hot-melt coating platforms.
• Skin-protective interface materials.
• Low-irritation adhesive technologies.

The commercial value is highest where the technology improves wear time, reduces skin reactions, or enables smaller patch dimensions. A patch that improves adherence but creates irritation may fail commercially despite strong drug-delivery performance.

5. Packaging and stability platforms

Barrier packaging is a practical opportunity because it can improve product quality without changing the drug formulation. Commercial targets include:

• Lower water-vapor transmission.
• Better resistance to cold-chain or heat excursions.
• Easier opening for patients with limited dexterity.
• Calendarized unit-dose systems.
• Institutional dispensing formats.

Packaging patents may provide a more defensible position than broad excipient substitutions if they claim a specific package configuration, moisture range, or stability outcome.

How does asenapine compare with competing antipsychotic products?

Asenapine competes with oral atypical antipsychotics such as aripiprazole, risperidone, olanzapine, quetiapine, and lurasidone. Its sublingual route and transdermal delivery system provide differentiation, but the active pharmaceutical ingredient does not have the market scale of the largest oral antipsychotics.

Product attribute	Asenapine sublingual	Asenapine transdermal	Conventional oral antipsychotics
Administration	Under tongue	Wearable patch	Swallowed
Taste issue	High	None during dosing	Usually low
Adherence value	Moderate	Potentially high	Variable
Manufacturing complexity	Moderate	High	Low to moderate
Generic entry barrier	Moderate	High	Variable
Excipient differentiation	High	High	Moderate
Device dependence	None	Yes	None

The transdermal product’s commercial opportunity is strongest in patients who have difficulty swallowing, resist oral medication, or benefit from visible administration tracking. Its risks include patch aversion, skin reactions, higher manufacturing cost, and payer reluctance.

What patent litigation and settlement issues affect asenapine?

Patent litigation risk is concentrated in ANDA challenges to listed sublingual-product patents and in any attempt to develop a competing transdermal system. A settlement may establish a negotiated generic entry date, supply arrangement, license, or other commercial terms.

Potential settlement structures include:

• Delayed generic entry.
• Authorized generic supply.
• Royalty-bearing license.
• Narrow patent carve-out.
• Agreement limited to one dosage form.
• Co-development or manufacturing rights.

The commercial impact depends on whether the agreement covers only Saphris or also affects Secuado-related technology. A settlement that permits sublingual entry does not necessarily resolve transdermal patent exposure.

What FDA regulatory pathway applies to new asenapine excipient products?

For a generic sublingual product, the likely route is an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[4]

A materially different formulation may require:

• A 505(b)(2) application.
• Clinical bridging or comparative exposure data.
• Comparative dissolution and performance testing.
• Human-factors work for packaging or delivery changes.
• New stability and extractables/leachables data.
• Additional local tolerability or adhesion studies for transdermal systems.

An excipient that is inactive in another oral dosage form is not automatically acceptable for sublingual or transdermal use. Route-specific exposure, local tolerability, absorption, and safety must be evaluated.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are:

• Uniform low-dose drug distribution.
• Control of tablet porosity and mechanical strength.
• Humidity-sensitive processing.
• Taste-masking reproducibility.
• Transdermal coating uniformity.
• Adhesive rheology.
• Residual drug control.
• Patch cutting, slitting, and pouching.
• Stability of drug-polymer mixtures.

The strongest IP position usually combines formulation claims with process claims. A competitor may design around an excipient claim but still face process or delivery-performance claims. Freedom-to-operate analysis should cover U.S., European, Japanese, and other commercially relevant jurisdictions because formulation and transdermal patents often have different claim scope and expiration dates by country.

Key Takeaways

• Asenapine has two commercial formulation platforms: sublingual tablets and a transdermal patch.
• Sublingual excipient value centers on rapid dissolution, taste masking, mechanical strength, and moisture protection.
• Transdermal value centers on adhesive performance, skin tolerability, drug flux, and patch stability.
• Saphris faces substantially higher generic substitution risk than Secuado.
• Asenapine is a small molecule, so biosimilar risk does not apply.
• The compound patent estate is mature; residual value lies in formulation, method-of-use, manufacturing, packaging, and transdermal-system claims.
• The most defensible commercial opportunities are taste-masked sublingual products, non-gelatin tablets, high-barrier packaging, and lower-irritation transdermal adhesive systems.
• Generic developers should treat excipient changes as bioequivalence and dissolution risks, not as simple cost-reduction exercises.
• Licensing value is higher for proprietary transdermal delivery and sensory technologies than for undifferentiated filler substitutions.

FAQs About Asenapine Excipient and Patent Strategy

Can asenapine be formulated as a conventional swallowed tablet?

Yes, but a swallowed tablet would represent a different product strategy. It would need to address systemic exposure, labeling, bioequivalence, and the clinical rationale for changing the approved sublingual route.

Is mannitol essential to every asenapine sublingual formulation?

No. Mannitol is used in the reference product, but alternative fillers or matrix materials may be possible if the formulation meets quality, dissolution, sensory, stability, and bioequivalence requirements.

Does a new asenapine excipient combination automatically receive patent protection?

No. Patentability depends on novelty, non-obviousness, adequate disclosure, and claim scope. A routine substitution of one conventional excipient for another is unlikely to support a strong patent position without an unexpected technical result.

Is Secuado protected by device patents or drug patents?

Potential protection can arise from both. Relevant claims may cover the drug-in-adhesive composition, patch structure, manufacturing process, dosing configuration, and therapeutic use.

What is the best commercial entry point for an excipient supplier?

The strongest targets are technologies that improve asenapine’s administration profile: taste masking for sublingual tablets, moisture-resistant packaging, non-gelatin rapidly dissolving matrices, and low-irritation transdermal adhesives.

References

1. U.S. Food and Drug Administration. (2009). Saphris (asenapine) sublingual tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2019). Secuado (asenapine) transdermal system: Prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application.